At a glance
ClinicalIndex Comparison RecordPhase 2Unknown· 18 target
Drug / intervention
MRG003+HX008drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Multi-center, Phase I/II Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of MRG003 in Combination With HX008 in Patients With EGFR-positive Advanced Solid Tumors
In Brief
A Phase 2 clinical trial evaluating MRG003+HX008 for Advanced Solid Tumors. Targeting 18 participants across 2 sites.
Detailed Summary
The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG003 in combination with HX008 in patients with EGFR-positive advanced or metastatic solid tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumors
CountriesChina
Collaborators--
Timeline
Phase 2UnknownOverdue
2023202420252026
Enrollment StartJun 2022
First PostedJan 2023
Primary CompletionMay 2025
Study CompletionJul 2025
TodayJul 2026
First PostedJan 18, 2023
Enrollment StartJun 30, 2022
Primary CompletionMay 1, 2025
Study CompletionJul 1, 2025
TodayJul 1, 2026
Enrollment to primary: 2.8 yearsPosted 3.5 years ago
Interventions
MRG003+HX008drug
Administered intravenously